BICO Group AB

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0013647385
SEK
19.61
-0.09 (-0.46%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About BICO Group AB stock-summary
stock-summary
BICO Group AB
Pharmaceuticals & Biotechnology
Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company operates as a provider of advanced bioprinting solutions for healthcare sector. The Company offers 3D bioprinting of human tissues and organs. The Company's technology facilitates the biofabrication of cell-laden anatomical structures with controlled cell density and homogenous distribution of viable cells. The cell-laden bioink structures are then cultured in vitro, under controlled conditions for a wide range of experiments. In addition, bioprinting with human cells can be combined with computer-aided design (CAD) and computer-aided manufacturing (CAM) using medical images from CT or MRI scans to create a blueprint (3D model) for bioprinting of patient-specific tissues and organs.
Company Coordinates stock-summary
Company Details
Arvid Wallgrens Backe 20 , GOETEBORG None : 413 46
stock-summary
Tel: 46 31 128700
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 2 Foreign Institutions (1.56%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Carsten Browall
Independent Chairman of the Board
Mr. Erik Gatenholm
Chief Executive Officer, Director
Ms. Ingela Hallberg
Independent Director
Mr. Bengt Sjoholm
Independent Director
Ms. Helena Skantorp
Independent Director
Mr. Christian Wildmoser
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
324 Million
(Quarterly Results - Jun 2025)
Net Profit:
-182 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 1,384 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.10

stock-summary
Return on Equity

-11.60%

stock-summary
Price to Book

0.76